Paired DNA-RNA testing enhances variant detection in colorectal

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Traditional DNA tests may overlook 10% of classic in familial adenomatous polyposis (FAP) cases. By integrating RNA sequencing, researchers unveiled novel APC variants in six families, explaining missed diagnoses due to abnormal gene splicing. The approach, DNA-RNA multigene panel testing, enhances detection rates, guiding family planning and treatment for FAP patients. Read more about this under Article 1 below.

Article 1: Solving missing heritability in patients with familial adenomatous polyposis with DNA-RNA paired testing

This study investigates patients with hereditary colorectal cancer predisposition due to APC gene variants. Traditional DNA-only testing may miss up to 10% of classic (FAP) cases. By adding RNA sequencing alongside DNA testing, researchers identified novel APC variants in six families. These variants caused abnormal gene splicing, explaining missed diagnoses. The approach, called paired DNA-RNA multigene panel testing, improves detection rates, aiding in family planning and treatment decisions for FAP patients and families. Read the full article .

In summary: Paired DNA-RNA testing improves detection of APC variants in familial adenomatous polyposis

Article 2: Exome copy number variant detection, analysis, and classification in a large cohort of families with undiagnosed rare genetic disease

Researchers utilised advanced methods to detect copy number variants (CNVs) from exome sequencing data in 6,633 families with rare genetic diseases. They identified 171 families (2.6%) with causal CNVs, ranging from small deletions to complex structural variants. Using established guidelines and additional criteria, they classified 151 CNVs as likely pathogenic/pathogenic and 20 as variants of uncertain significance. This approach enhances diagnostic yield for undiagnosed cases, offering a cost-effective alternative to genome sequencing and improving CNV pathogenicity assessment. Read the full article .

In summary: Advanced CNV detection enhances diagnostic yield in rare genetic diseases

Article 3: A genome-wide spectrum of tandem repeat expansions in 338,963 humans

The Genome Aggregation Database (gnomAD) has been a vital resource for understanding human genetic variation. However, it has largely overlooked tandem repeat (TR) expansions, despite their association with over 50 human diseases. This study introduces TR-gnomAD, a reference of 0.86 million TRs from diverse whole-genome sequencing samples. TR-gnomAD reveals ancestry-specific disease patterns and distinguishes between common and potentially harmful TR expansions, aiding researchers and physicians in interpreting TR-related genetic diseases. Access TR-gnomAD at . Read the full article .

In summary: TR-gnomAD: A new resource for understanding tandem repeat expansions

Article 4: Clinical effectiveness of newborn screening for spinal muscular atrophy: A nonrandomised controlled trial

Early detection and treatment are crucial for (SMA) outcomes. This study compared infants diagnosed through newborn screening with those diagnosed after symptoms appeared. Analysing data from 234 children, it found those screened at birth achieved motor milestones better than clinically diagnosed infants. Most newborn-screened infants gained independent sitting and walking abilities, highlighting the effectiveness of newborn screening in improving SMA outcomes. This emphasises the importance of early detection programs for better management of SMA. Read the full article .

In summary: Early detection improves outcomes in spinal muscular atrophy

Last updated: 17.09.2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases
  • OncoSentia MRD

    Tumour-agnostic, plasma-informed liquid biopsy assay to detect and longitudinally monitor circulating tumour DNA (ctDNA) in patients with stage III unresectable NSCLC enabling molecular assessment during and after treatment, complementing established clinical and radiological monitoring.

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?